NASDAQ:OPK - Opko Health Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.50
  • Forecasted Upside: 30.95 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$4.20
▲ +0.2 (5.00%)
1 month | 3 months | 12 months
Get New Opko Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OPK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OPK

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$5.50
▲ +30.95% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Opko Health in the last 3 months. The average price target is $5.50, with a high forecast of $10.00 and a low forecast of $2.50. The average price target represents a 30.95% upside from the last price of $4.20.
Buy
The current consensus among 3 polled investment analysts is to buy stock in Opko Health.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/8/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/6/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/4/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/2/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/2/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/31/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/29/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2020

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/31/2020Piper SandlerBoost Price Target$6.00 ➝ $10.00High
i
Rating by Edward Tenthoff at Piper Sandler
7/31/2020Barrington ResearchReiterated RatingBuyMedium
i
Rating by M. Petusky at Barrington Research
7/8/2020Piper SandlerBoost Price Target$4.00 ➝ $6.00Medium
i
Rating by Edward Tenthoff at Piper Sandler
6/9/2020Piper SandlerBoost Price Target$3.00 ➝ $4.00High
i
Rating by Edward Tenthoff at Piper Sandler
6/8/2020Piper SandlerReiterated RatingBuy$3.00High
i
Rating by Edward Tenthoff at Piper Sandler
5/7/2020Barrington ResearchReiterated RatingBuy$4.00High
i
Rating by M. Petusky at Barrington Research
4/29/2020Piper SandlerReiterated RatingBuy$3.00Medium
i
Rating by Edward Tenthoff at Piper Sandler
3/10/2020Piper SandlerBoost Price Target$2.50 ➝ $3.00High
i
Rating by Edward Tenthoff at Piper Sandler
3/6/2020Piper SandlerReiterated RatingBuy$2.50 ➝ $3.00High
i
Rating by Edward Tenthoff at Piper Sandler
2/27/2020Barrington ResearchReiterated RatingBuy$4.00Medium
i
Rating by M. Petusky at Barrington Research
11/25/2019Piper Jaffray CompaniesInitiated CoverageOverweight$2.50High
i
9/12/2019Barrington ResearchReiterated RatingBuy$4.00Medium
i
2/28/2019Barrington ResearchReiterated RatingBuy$5.00Low
i
11/12/2018Barrington ResearchReiterated RatingBuy$7.00Medium
i
10/5/2018Barrington ResearchReiterated RatingBuy$7.00Low
i
8/7/2018Cantor FitzgeraldReiterated RatingBuy$20.00High
i
Rating by Louise Chen at Cantor Fitzgerald
5/9/2018Barrington ResearchReiterated RatingBuy$7.00Medium
i
5/8/2018Cantor FitzgeraldReiterated RatingBuy$20.00High
i
Rating by Louise Chen at Cantor Fitzgerald
3/2/2018JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$7.00High
i
3/1/2018Cantor FitzgeraldSet Price TargetBuy$20.00High
i
Rating by Louise Chen at Cantor Fitzgerald
10/25/2017Cantor FitzgeraldSet Price TargetBuy$20.00N/A
i
10/12/2017Cantor FitzgeraldSet Price TargetBuy$20.00N/A
i
9/25/2017LADENBURG THALM/SH SHReiterated RatingBuy$16.00Medium
i
9/14/2017JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$12.00 ➝ $7.00High
i
8/17/2017Cantor FitzgeraldInitiated CoverageOverweight$20.00Medium
i
8/10/2017Jefferies Financial GroupReiterated RatingHold$6.80 ➝ $6.50High
i
7/27/2017Jefferies Financial GroupReiterated RatingHold$8.00Low
i
7/18/2017Barrington ResearchBoost Price TargetOutperform$11.00Medium
i
6/16/2017LADENBURG THALM/SH SHReiterated RatingBuy$19.50Medium
i
6/13/2017Jefferies Financial GroupReiterated RatingHold$8.00N/A
i
6/12/2017Jefferies Financial GroupReiterated RatingHold$8.00Medium
i
6/6/2017LADENBURG THALM/SH SHReiterated RatingBuy$19.50Low
i
3/14/2017GuggenheimInitiated CoverageBuy$25.00High
i
3/5/2017Standpoint ResearchReiterated RatingBuy$14.00N/A
i
3/2/2017Jefferies Financial GroupLower Price TargetHold$10.00 ➝ $8.00N/A
i
1/3/2017LaidlawReiterated RatingBuy$22.00 ➝ $19.00N/A
i
1/3/2017LADENBURG THALM/SH SHReiterated RatingBuy$20.00 ➝ $19.50N/A
i
12/30/2016Standpoint ResearchReiterated RatingBuy ➝ BuyN/A
i
10/10/2016OppenheimerReiterated RatingHoldN/A
i
Rating by Marcus Y. Ho at Oppenheimer Holdings Inc.
10/10/2016Jefferies Financial GroupReiterated RatingHold$10.00N/A
i
Rating by Brandon Couillard at Jefferies Financial Group Inc.
8/17/2016Jefferies Financial GroupReiterated RatingHoldN/A
i
Rating by Brandon Couillard at Jefferies Financial Group Inc.
8/11/2016OppenheimerReiterated RatingMarket PerformN/A
i
Rating by Rohit Vanjani at Oppenheimer Holdings Inc.
8/9/2016JPMorgan Chase & Co.Set Price TargetBuy$14.00N/A
i
Rating by dana flanders at JPMorgan Chase & Co.
6/25/2016OppenheimerReiterated RatingOutperformN/A
i
Rating by Rohit Vanjani at Oppenheimer Holdings Inc.
6/21/2016Standpoint ResearchBoost Price TargetBuy$16.00 ➝ $18.00N/A
i
Rating by Ronnie Moas at Standpoint Research
6/17/2016Jefferies Financial GroupReiterated RatingHold$11.00 ➝ $10.00N/A
i
Rating by Brandon Couillard at Jefferies Financial Group Inc.
6/16/2016OppenheimerReiterated RatingHoldN/A
i
Rating by Rohit Vanjani at Oppenheimer Holdings Inc.
6/16/2016Deutsche Bank AktiengesellschaftLower Price TargetHold$11.00 ➝ $10.00N/A
i
6/3/2016Standpoint ResearchInitiated CoverageBuy$16.00N/A
i
5/31/2016OppenheimerReiterated RatingHoldN/A
i
Rating by Rohit Vanjani at Oppenheimer Holdings Inc.
5/10/2016OppenheimerReiterated RatingHoldN/A
i
Rating by Rohit Vanjani at Oppenheimer Holdings Inc.
4/27/2016LADENBURG THALM/SH SHReiterated RatingBuyN/A
i
Rating by Sharon Stein at LADENBURG THALM/SH SH
4/1/2016Jefferies Financial GroupReiterated RatingHold$11.00N/A
i
3/31/2016LADENBURG THALM/SH SHReiterated RatingBuyN/A
i
Rating by Kevin Degeeter at LADENBURG THALM/SH SH
3/31/2016Barrington ResearchLower Price TargetOutperform$17.00 ➝ $16.00N/A
i
3/15/2016Jefferies Financial GroupReiterated RatingHoldN/A
i
3/2/2016OppenheimerReiterated RatingMarket PerformN/A
i
(Data available from 10/29/2015 forward)
Opko Health logo
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The company's Pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, a selective androgen receptor modulator for benign prostatic hyperplasia, and other urologic and metabolic conditions; and OPK88003, a once or twice weekly oxyntomodulin that is in Phase II trials for type 2 diabetes and obesity. It is also developing hGH-CTP, a once-weekly human growth hormone injection in Phase III clinical trial in partnership with Pfizer, Inc.; VARUBI for chemotherapy-induced nausea and vomiting; and Factor VIIa drug for hemophilia. In addition, this segment develops and produces specialty active pharmaceutical ingredients; and discovers drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, it develops, manufactures, markets, and sells pharmaceutical, nutraceutical, and veterinary products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro- intestinal products, hormones, and others. Additionally, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.
Read More

Today's Range

Now: $4.20
$3.93
$4.25

50 Day Range

MA: $3.77
$2.99
$4.62

52 Week Range

Now: $4.20
$1.12
$6.47

Volume

11,425,663 shs

Average Volume

14,186,616 shs

Market Capitalization

$2.81 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.9